BioCryst's stock is currently priced at $7.60, reflecting a slight increase of 0.33$0.025. The stock has fluctuated between $7.57 and$7.92 today, with a 52-week high of $11.31 and a low of$6. The company's market capitalization stands at approximately $1.6 billion, with a trading volume of 1,923,583 shares today. The expanded approval of ORLADEYO is expected to enhance BioCryst's market presence and impact. By extending the reach of their treatment to a younger demographic, the company is well-positi ...